EHA: Adding Pirtobrutinib to Venetoclax-Rituximab ups progression-free survival in chronic lymphocytic leukemia
For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), adding pirtobrutinib to venetoclax-rituximab (PVR) yields improved progression-free survival (PFS) compared to venetoclax-rituximab (VR), according ...
Jul 2, 2026
0
3









